These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28526024)

  • 1. PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.
    Cerrato E; Quirós A; Echavarría-Pinto M; Mejia-Renteria H; Aldazabal A; Ryan N; Gonzalo N; Jimenez-Quevedo P; Nombela-Franco L; Salinas P; Núñez-Gil IJ; Rumoroso JR; Fernández-Ortiz A; Macaya C; Escaned J
    Cardiovasc Diabetol; 2017 May; 16(1):68. PubMed ID: 28526024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
    Park SD; Baek YS; Woo SI; Kim SH; Shin SH; Kim DH; Kwan J; Park KS
    Trials; 2014 May; 15():151. PubMed ID: 24885437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study.
    Janssens GN; van Leeuwen MAH; van der Hoeven NW; de Waard GA; Nijveldt R; Diletti R; Zijlstra F; von Birgelen C; Escaned J; Valgimigli M; van Royen N
    J Cardiovasc Transl Res; 2016 Jun; 9(3):249-256. PubMed ID: 27102290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.
    Kaul U; Mansoor AH
    Indian Heart J; 2012; 64(1):54-9. PubMed ID: 22572427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
    Baos S; Underwood W; Culliford L; Reeves BC; Rogers CA; Bowles R; Johnson T; Baumbach A; Mumford A
    Trials; 2017 Nov; 18(1):529. PubMed ID: 29121979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
    Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
    Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
    Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
    Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
    Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
    Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial.
    Rosenson RS; Chen Q; Najera SD; Lee ML; Cho DJ
    Cardiovasc Drugs Ther; 2018 Oct; 32(5):443-451. PubMed ID: 30074112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.
    Pelletier-Galarneau M; Hunter CRRN; Ascah KJ; Beanlands RSB; Dwivedi G; deKemp RA; Chow BJW; Ruddy TD
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28465300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.